Samples from metastatic melanoma patients treated sequentially with immunotherapies targeting CTLA4 and PD-1 pointed to response-related tumor features.
Mutation and predicted neoantigen profiles for more than 63,000 tumors suggests it would be difficult to design a broadly beneficial cancer vaccine.
The firm will apply the proceeds towards an early-stage clinical trial of a precision colorectal cancer vaccine.
The partners will use Protagen’s autoantibody measuring technology to identify biomarkers of patient response to cancer immunotherapies.
The results of the Harvard-led study suggest that the immune system struggles to infiltrate and attack tumors with more aneuploidy.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
The firm's vaccine, which previously led to tumor regression in a patient with metastatic breast cancer, is scheduled to enter clinical trials in 2017.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.
The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.